Clinical Trials Logo

Metastasis clinical trials

View clinical trials related to Metastasis.

Filter by:

NCT ID: NCT05755347 Not yet recruiting - Breast Cancer Clinical Trials

Assessing Functional Status Needs Via PRO Measures for Pts With Metastatic Breast Cancer

Start date: March 2023
Study type: Observational

The purpose of this single-site non-randomized study is to identify areas of need related to functional status and overall health, including nutrition and mental health in subjects with metastatic breast cancer (MBC). A decline in functional status is observed after breast cancer diagnosis and exacerbated by treatment. Declining functional status impacts the quality of life and can lead to increased comorbidity burden, hospitalization, and increased mortality. Functional status is assessed by specific provider-graded scales. Patient Reported Outcome (PRO) measures may better assess certain aspects of patient health and symptom domains. Thus, potentially supporting the future implementation of effective prehabilitation strategies. This study explores whether a PRO-based survey will identify the physical and emotional health and the social and financial status of patients newly diagnosed with MBC.

NCT ID: NCT05610293 Active, not recruiting - Surgery Clinical Trials

T1 Squamous Cell Carcinomas of the Lip

Start date: April 1, 2021
Study type: Observational

The purpose of this study is to investigate the risk of recurrence and metastasis in patients treated with different surgical margins (5mm vs 10mm) for a T1 squamous cell carcinoma of the lip.

NCT ID: NCT05542407 Not yet recruiting - Endometrial Cancer Clinical Trials

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Start date: April 15, 2023
Phase: Phase 1
Study type: Interventional

Endometrial cancer (EC) is the fourth most common cancer in United States women, and alarmingly, the frequency and mortality from EC continues to rise, in part due to the obesity epidemic. Obese women with EC have a 6.3-fold increased risk of death from this disease, as compared to their non-obese counterparts. Patients with advanced/recurrent EC are unlikely to be cured by surgery, conventional chemotherapy (paclitaxel + carboplatin is the standard first-line treatment), radiation, or a combination of these. Thus, new treatments for EC are desperately needed as well as a better understanding of the impact of obesity on EC biology and treatment. The purpose of this study is to test the safety of a combination of treatments, atezolizumab and ONC201, given based on body weight, to treat endometrial cancer. Using the combination of atezolizumab and ONC201, has not been approved by the Food and Drug Administration (FDA) for the treatment of endometrial cancer. This clinical trial will examine the treatment of atezolizumab + ONC201 in obese and non-obese subjects with metastatic/recurrent EC.

NCT ID: NCT05539183 Not yet recruiting - Solid Tumor Clinical Trials

Collection of Pleural Effusion Fluid

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

At the Laboratory for Molecular and Cellular Therapy (LMCT) of the Vrije Universiteit Brussel, Belgium, we study resistance mechanisms that hamper effective immunotherapy for solid cancer patients. To perform clinically relevant research, we apply autologous human material for functional assessment. The latter requires viable tumor and immune cells. Solid cancer patients with pleural metastasis often develop pleural effusion. Notably, upon pleural drainage, residual material is obtained that consists of histocompatible tumor and immune cells. Hence with this study, we want to obtain blood and pleural effusion fluid drawn from solid cancer patients with pleural metastases to: 1. Collect, enrich and store primary cells derived from residual pleural effusion fluid and blood at the LMCT (VUB, Belgium) 2. Evaluate characteristics of the cells (phenotype, function,...) and compare content of pleural effusate with blood and clinicopathologic features of the patients.

NCT ID: NCT05338658 Not yet recruiting - Solid Tumor Clinical Trials

Study of PAT in Patients With Solid Tumor Cancers

Start date: April 30, 2023
Phase: Phase 1
Study type: Interventional

This is a single center Phase I study with extension of peptide alarm therapy (PAT) administered by intratumoral (IT) injection during the 1st course of a standard of care intravenous PD-1/PD-L1 inhibitor for the treatment of locally advanced or metastatic solid tumor cancers that has failed to be controlled after one or more prior therapies including a previous PD-1/PD-L1 inhibitor

NCT ID: NCT05288608 Recruiting - Metastasis Clinical Trials

Evaluation of Fast, Same-day Delivery of Palliative Radiotherapy Without a Planning CT (FAST-METS)

Start date: December 16, 2021
Study type: Observational

Palliative radiotherapy is an effective treatment for patients with painful bone metastases. Standard workflows often involve long waiting times or multiple visits. Fast palliation completed during a single clinic visit can be achieved by omitting a planning CT scan, and using available diagnostic imaging for treatment planning. The adaptive treatment platforms provides the possibility to adapt positions differences between the diagnostic CT and radiotherapy treatment of the target and organs at risk. In this study, the investigators will investigate the experiences of patients who have been treated with this fast-adaptive workflow (FAST-METS) using 2 questionnaires.

NCT ID: NCT05223608 Recruiting - Solid Tumor, Adult Clinical Trials

Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy

Start date: March 3, 2022
Phase: N/A
Study type: Interventional

ImmuCCo-1905 is a monocentric interventional study on patients treated by immunotherapy, which consist in establishment of a prospective clinic-biologic database over 5 years, associated with a biobank. This database will allow carrying out works aiming at assessing immunotherapy in real life situation.

NCT ID: NCT05208372 Recruiting - Stomach Neoplasms Clinical Trials

Detection of CTC and ctDNA in the Diagnosis of Metastasis in Gastric Cancer

Start date: January 1, 2022
Study type: Observational

To investigate the value of CTCs and ctDNA in the diagnosis of metastasis in ascites/peritoneal flushing fluid and blood; To investigate the influence of laparoscopic CO2 pneumoperitoneum establishment on peritoneal and hematogenous metastasis of advanced gastric cancer; To explore the influence of the number and type of CTCs and ctDNA on metastasis and prognosis.

NCT ID: NCT05200273 Not yet recruiting - Metastasis Clinical Trials

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114

Start date: March 15, 2022
Phase: Phase 1
Study type: Interventional

A Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK114.

NCT ID: NCT05103358 Recruiting - Cancer Clinical Trials

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Start date: February 15, 2022
Phase: Phase 2
Study type: Interventional

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes